scholarly journals Immunoglobulin E–Selective Immunoadsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis

2019 ◽  
Vol 139 (3) ◽  
pp. 720-723 ◽  
Author(s):  
Kristian Reich ◽  
Anna Hartjen ◽  
Jeremias Reich ◽  
Julie Schröder ◽  
Nadine Steingrube ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Immunoglobulin E ◽  
Severe Atopic Dermatitis

scholarly journals Metabolomics Distinguishes DOCK8 Deficiency from Atopic Dermatitis: Towards a Biomarker Discovery

Metabolites ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 274 ◽  
Author(s):  
Minnie Jacob ◽  
Xinyun Gu ◽  
Xian Luo ◽  
Hamoud Al-Mousa ◽  
Rand Arnaout ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Biomarker Discovery ◽  
Isotope Labeling ◽  
Immunoglobulin E ◽  
Clinical Symptoms ◽  
Elevated Serum ◽  
Severe Atopic Dermatitis ◽  
Serum Ige ◽  
Tryptophan Degradation ◽  
Dock8 Deficiency

Bi-allelic mutations in the dedicator of cytokinesis 8 (DOCK8) are responsible for a rare autosomal recessive primary combined immunodeficiency syndrome, characterized by atopic dermatitis, elevated serum Immunoglobulin E (IgE) levels, recurrent severe cutaneous viral infections, autoimmunity, and predisposition to malignancy. The molecular link between DOCK8 deficiency and atopic skin inflammation remains unknown. Severe atopic dermatitis (AD) and DOCK8 deficiency share some clinical symptoms, including eczema, eosinophilia, and increased serum IgE levels. Increased serum IgE levels are characteristic of, but not specific to allergic diseases. Herein, we aimed to study the metabolomic profiles of DOCK8-deficient and AD patients for potential disease-specific biomarkers using chemical isotope labeling liquid chromatography-mass spectrometry (CIL LC-MS). Serum samples were collected from DOCK8-deficient (n = 10) and AD (n = 9) patients. Metabolomics profiling using CIL LC-MS was performed on patient samples and compared to unrelated healthy controls (n = 33). Seven metabolites were positively identified, distinguishing DOCK8-deficient from AD patients. Aspartic acid and 3-hydroxyanthranillic acid (3HAA, a tryptophan degradation pathway intermediate) were up-regulated in DOCK8 deficiency, whereas hypotaurine, leucyl-phenylalanine, glycyl-phenylalanine, and guanosine were down-regulated. Hypotaurine, 3-hydroxyanthranillic acid, and glycyl-phenylalanine were identified as potential biomarkers specific to DOCK8 deficiency. Aspartate availability has been recently implicated as a limiting metabolite for tumour growth and 3HAA; furthermore, other tryptophan metabolism pathway-related molecules have been considered as potential novel targets for cancer therapy. Taken together, perturbations in tryptophan degradation and increased availability of aspartate suggest a link of DOCK8 deficiency to oncogenesis. Additionally, perturbations in taurine and dipeptides metabolism suggest altered antixidation and cell signaling states in DOCK8 deficiency. Further studies examining the mechanisms underlying these observations are necessary.

Proactive treatment appears to decrease serum immunoglobulin-E levels in patients with severe atopic dermatitis

2010 ◽  
Vol 163 (5) ◽  
pp. 1127-1129 ◽  
Author(s):  
T. Fukuie ◽  
I. Nomura ◽  
K. Horimukai ◽  
A. Manki ◽  
I. Masuko ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Immunoglobulin E ◽  
Serum Immunoglobulin ◽  
Severe Atopic Dermatitis

scholarly journals Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients

2016 ◽  
Vol 8 (2) ◽  
pp. 179-184 ◽  
Author(s):  
Rachael C. Saporito ◽  
David J. Cohen
Keyword(s):  
Atopic Dermatitis ◽  
Case Report ◽  
Immunoglobulin E ◽  
Interleukin 4 ◽  
Severe Atopic Dermatitis ◽  
T Helper ◽  
Novel Therapy ◽  
T Helper 2 ◽  
American Children ◽  
Bacterial Superinfection

Atopic dermatitis (AD) is a chronic, pruritic skin disease often complicated by bacterial superinfection affecting 10.7% of American children. The pathogenesis involves a skin barrier breakdown in addition to dysfunctional innate and adaptive immune response, including an unbalanced increase in T-helper 2 cells and hyperimmunoglobulinemia E. The increased numbers of T-helper 2 cells are involved in stimulating the production of immunoglobulin E and eosinophilia by releasing interleukin-4, -5, and -13 as well as in decreasing protection against bacterial superinfection by releasing interleukin-10. The current Food and Drug Administration-approved symptomatic treatment for AD includes topical ointments, topical and systemic corticosteroids, topical immunomodulant therapy, antibiotics, and phototherapy, but there are not approved targeted therapies or cures. By presenting a case of an 8-year-old African-American boy, this case report supports novel therapy of moderate-to-severe AD with apremilast, a phosphodiesterase type 4 inhibitor. Apremilast has recently completed the phase 2 clinical trial (NCT02087943) for treatment of AD in adults. This case report illustrates the potential for apremilast as a treatment for AD in children, where there is a great need for safe and effective medications.

scholarly journals Hyperbaric Oxygen Therapy (HBOT) as a Therapeutic Option for Patients with Atopic Dermatitis (AD) – Own Experiences and Literature Review

2017 ◽  
Vol 60 (3) ◽  
pp. 13-18
Author(s):  
Romuald Olszański ◽  
Maciej Konarski ◽  
Piotr Siermontowski
Keyword(s):  
Atopic Dermatitis ◽  
Hyperbaric Oxygen ◽  
Hyperbaric Oxygen Therapy ◽  
Oxygen Therapy ◽  
Immunoglobulin E ◽  
Therapeutic Option ◽  
Treatment Plan ◽  
Local Treatment ◽  
Complement C3 ◽  
Severe Atopic Dermatitis

Abstract The paper discusses the treatment results of ten patients with severe atopic dermatitis (AD) who did not respond to standard pharmacotherapy and underwent hyperbaric oxygen therapy (HBOT). Each patient was subject to 10 oxygen exposures at pO2 2.5 ATA (~ 250 kPa) with the duration time of 60 minutes. In the period of implementation of the hyperbaric procedures the general treatment plan was suspended for all patients while maintaining typical local treatment. Clinical evaluation was performed in the study group as well as determination of levels of immunoglobulins: IgA, IgG, IgM and IgE and C3 and C4 complement. All patients indicated clinical improvement and a decreased IgE immunoglobulin and complement C3 level upon the completion of the exposure cycle. Taking into account the authors’ own observations and data from literature, an overall improvement in the clinical status and a decrease in the level of immunoglobulin E and C3 complement following a cycle of exposures may be indicative of an immunomodulating HBOT effect on AD, whereas hyperbaric oxygenation may constitute a therapeutic option for some patients with AD, especially those exhibiting a poor response to standard treatment.

Sign in / Sign up

Export Citation Format

Share Document